<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02121002</url>
  </required_header>
  <id_info>
    <org_study_id>AM-DCG-001</org_study_id>
    <nct_id>NCT02121002</nct_id>
  </id_info>
  <brief_title>Study Comparing a Generic Diclofenac Sodium Topical Gel, 1% to Voltaren in the Treatment of Subjects With Osteoarthritis of the Knee</brief_title>
  <official_title>A Multi-Center, Double-Blind, Vehicle-Controlled, Parallel-Group Study Comparing a Generic Diclofenac Sodium Topical Gel, 1% to Voltaren® Gel (Diclofenac Sodium Topical Gel) 1% in the Treatment of Subjects With Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amneal Pharmaceuticals, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sristek Clinical Research Solutions Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Amneal Pharmaceuticals, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish the therapeutic equivalence and safety of a generic Diclofenac Sodium Topical&#xD;
      Gel, 1% with Voltaren® Gel 1% in subjects with osteoarthritis of the knee.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to 4 Weeks in WOMAC Pain Score</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Mean change from baseline to week 4 in the Western Ontario McMaster&#xD;
Osteoarthritis (WOMAC) pain score:&#xD;
5-point Likert scale: none=o, mild=1, moderate=2, severe=3, extreme=4</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1176</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Diclofenac Sodium Topical Gel, 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Voltaren Topical Gel, 1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Voltaren Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Diclofenac Sodium Topical Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle Diclofenac Sodium Topical Gel. 4 gm, 4 times a day for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac Sodium Topical Gel, 1%</intervention_name>
    <description>Opaque, white gel</description>
    <arm_group_label>Diclofenac Sodium Topical Gel, 1%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voltaren Topical Gel, 1%</intervention_name>
    <description>Opaque, white gel</description>
    <arm_group_label>Voltaren Topical Gel, 1%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Diclofenac Sodium Topical Gel</intervention_name>
    <description>Opaque, white gel</description>
    <arm_group_label>Vehicle Diclofenac Sodium Topical Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy, ambulatory male or non-pregnant female subjects aged ≥ 35 years with a&#xD;
             clinical diagnosis of OA of the knee.&#xD;
&#xD;
          -  Had an X-ray of the target knee, taken no more than 1 year before baseline, showing&#xD;
             evidence of OA with Kellgren-Lawrence grade 1-3 disease.&#xD;
&#xD;
          -  After discontinuing all pain medications for at least 7 days, has at least moderate&#xD;
             pain on movement for target knee&#xD;
&#xD;
          -  If female and of child-bearing potential, agree to abstain from sexual intercourse or&#xD;
             use a reliable method of contraception during the study&#xD;
&#xD;
          -  Able to tolerate rescue medication with paracetamol/acetaminophen.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating or planning to become pregnant during the study period.&#xD;
&#xD;
          -  X-ray showing evidence of OA with Kellgren-Lawrence grade 4 disease.&#xD;
&#xD;
          -  History of OA pain in the contralateral knee requiring medication within 1 year prior&#xD;
             to screening.&#xD;
&#xD;
          -  After discontinuing all pain medications for at least 7 days, has a baseline score of&#xD;
             ≥20 mm on a 0-100 mm Visual Analog Scale (VAS) for the contralateral knee immediately&#xD;
             prior to randomization.&#xD;
&#xD;
          -  History of secondary OA, rheumatoid arthritis, chronic inflammatory disease or&#xD;
             fibromyalgia.&#xD;
&#xD;
          -  History of asthma, hypertension, myocardial infarction, thrombotic events, stroke,&#xD;
             congestive heart failure, impaired renal function or liver disease.&#xD;
&#xD;
          -  History of gastrointestinal bleeding or peptic ulcer disease.&#xD;
&#xD;
          -  Use of warfarin or other anticoagulant therapy within 30 days of study randomization.&#xD;
&#xD;
          -  Elevated transaminases at screening.&#xD;
&#xD;
          -  Use of ACE inhibitors, cyclosporine, diuretics, lithium or methotrexate, within 30&#xD;
             days of study randomization.&#xD;
&#xD;
          -  Concomitant use of corticosteroids or use within 30 days of study randomization.&#xD;
&#xD;
          -  Concomitant acetylsalicylic acid therapy other than a stable low dose used for cardiac&#xD;
             prophylaxis taken for at least 3 months prior to enrollment and maintained throughout&#xD;
             the duration of the study.&#xD;
&#xD;
          -  Known allergy to aspirin or nonsteroidal anti-inflammatory drug&#xD;
&#xD;
          -  Any other acute or chronic illness that could compromise the integrity of study data&#xD;
             or place the subject at risk by participating in the study.&#xD;
&#xD;
          -  Receipt of any drug as part of a research study within 30 days prior to screening.&#xD;
&#xD;
          -  Previous participation in this study.&#xD;
&#xD;
          -  Any use between screening and baseline of a treatment or medication that may&#xD;
             potentially confound study assessment that may potentially confound study assessment&#xD;
             (e.g. use of topical analgesics or anti-inflammatory drugs).&#xD;
&#xD;
          -  Recent history of major knee injury or surgery.&#xD;
&#xD;
          -  Known history of positive HIV&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prayag Shah, MD</last_name>
    <role>Study Director</role>
    <affiliation>Amneal Pharmaceuticals, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sunshine Hospitals</name>
      <address>
        <city>Secunderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King George Hospital</name>
      <address>
        <city>Visakhapatnam</city>
        <state>Andhra Pradesh</state>
        <zip>530002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King George Hospital</name>
      <address>
        <city>Visakhapatnam</city>
        <state>Andra Pradesh</state>
        <zip>530002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rathi Orthopedic and Research Centre</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380 015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>B. J. Medical College &amp; Hospital</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GMERS Medical College and Hospital</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380061</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shir Hatkesh Sarvajanik Tabibi Chikitsha Kendra</name>
      <address>
        <city>Junagadh</city>
        <state>Gujarat</state>
        <zip>362 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre For Knee Surgery</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat</state>
        <zip>390007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shree Giriraj Multispeciality Hospital</name>
      <address>
        <city>Rajkot</city>
        <state>Gujurat</state>
        <zip>360007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Johns Medical College</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K L E Societys Jawaharlal Nehry Medical College</name>
      <address>
        <city>Belgaum</city>
        <state>Karnataka</state>
        <zip>590010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mysore Medical College</name>
      <address>
        <city>Mysore</city>
        <state>Karnataka</state>
        <zip>570001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Government Medical College, Calicut</name>
      <address>
        <city>Calicut</city>
        <state>Kerala</state>
        <zip>673008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psm Dept Ltmmc &amp; Ltmg Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400022</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Government Medical College</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jasleen Hospital</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lata Mangeshkar Hospital</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440019</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bj Medical College</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malpani Multispeciality Hospital</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302023</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Speciality Hospitals</name>
      <address>
        <city>Madurai</city>
        <state>Tamil Nadu</state>
        <zip>625020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M V Hospital and Research Centre</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <zip>226 003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Georges Medical University</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <zip>226003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Goa Medical College</name>
      <address>
        <city>Goa</city>
        <zip>403716</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 21, 2014</study_first_submitted>
  <study_first_submitted_qc>April 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2014</study_first_posted>
  <results_first_submitted>April 30, 2021</results_first_submitted>
  <results_first_submitted_qc>May 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 16, 2021</results_first_posted>
  <disposition_first_submitted>June 23, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>June 23, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 16, 2015</disposition_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Knee</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Diclofenac Sodium Topical Gel, 1%</title>
          <description>Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks&#xD;
Diclofenac Sodium Topical Gel, 1%: Opaque, white gel</description>
        </group>
        <group group_id="P2">
          <title>Voltaren Topical Gel, 1%</title>
          <description>Voltaren Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks&#xD;
Voltaren Topical Gel, 1%: Opaque, white gel</description>
        </group>
        <group group_id="P3">
          <title>Vehicle Diclofenac Sodium Topical Gel</title>
          <description>Vehicle Diclofenac Sodium Topical Gel. 4 gm, 4 times a day for 4 weeks&#xD;
Vehicle Diclofenac Sodium Topical Gel: Opaque, white gel</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="392"/>
                <participants group_id="P2" count="393"/>
                <participants group_id="P3" count="391"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="385"/>
                <participants group_id="P2" count="389"/>
                <participants group_id="P3" count="381"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Concomitant therapy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Others</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline participants in the Safety population.</population>
      <group_list>
        <group group_id="B1">
          <title>Diclofenac Sodium Topical Gel, 1%</title>
          <description>Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks&#xD;
Diclofenac Sodium Topical Gel, 1%: Opaque, white gel</description>
        </group>
        <group group_id="B2">
          <title>Voltaren Topical Gel, 1%</title>
          <description>Voltaren Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks&#xD;
Voltaren Topical Gel, 1%: Opaque, white gel</description>
        </group>
        <group group_id="B3">
          <title>Vehicle Diclofenac Sodium Topical Gel</title>
          <description>Vehicle Diclofenac Sodium Topical Gel. 4 gm, 4 times a day for 4 weeks&#xD;
Vehicle Diclofenac Sodium Topical Gel: Opaque, white gel</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="391"/>
            <count group_id="B2" value="393"/>
            <count group_id="B3" value="391"/>
            <count group_id="B4" value="1175"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;= 18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="357"/>
                    <measurement group_id="B2" value="351"/>
                    <measurement group_id="B3" value="354"/>
                    <measurement group_id="B4" value="1062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="255"/>
                    <measurement group_id="B2" value="244"/>
                    <measurement group_id="B3" value="254"/>
                    <measurement group_id="B4" value="753"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="137"/>
                    <measurement group_id="B4" value="422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to 4 Weeks in WOMAC Pain Score</title>
        <description>Mean change from baseline to week 4 in the Western Ontario McMaster&#xD;
Osteoarthritis (WOMAC) pain score:&#xD;
5-point Likert scale: none=o, mild=1, moderate=2, severe=3, extreme=4</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Across study groups, the per protocol (PP) population included 1147 subjects (97.53%) and the modified intention-to-treat (mITT) population included 1166 subjects (99.15%).&#xD;
For various reasons, 10 subjects were excluded from mITT population while 29 subjects were excluded from PP population out of 1176 subjects randomized in the study</population>
        <group_list>
          <group group_id="O1">
            <title>Diclofenac Sodium Topical Gel, 1%</title>
            <description>Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks&#xD;
Diclofenac Sodium Topical Gel, 1%: Opaque, white gel</description>
          </group>
          <group group_id="O2">
            <title>Voltaren Topical Gel, 1%</title>
            <description>Voltaren Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks&#xD;
Voltaren Topical Gel, 1%: Opaque, white gel</description>
          </group>
          <group group_id="O3">
            <title>Vehicle Diclofenac Sodium Topical Gel</title>
            <description>Vehicle Diclofenac Sodium Topical Gel. 4 gm, 4 times a day for 4 weeks&#xD;
Vehicle Diclofenac Sodium Topical Gel: Opaque, white gel</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 4 Weeks in WOMAC Pain Score</title>
          <description>Mean change from baseline to week 4 in the Western Ontario McMaster&#xD;
Osteoarthritis (WOMAC) pain score:&#xD;
5-point Likert scale: none=o, mild=1, moderate=2, severe=3, extreme=4</description>
          <population>Across study groups, the per protocol (PP) population included 1147 subjects (97.53%) and the modified intention-to-treat (mITT) population included 1166 subjects (99.15%).&#xD;
For various reasons, 10 subjects were excluded from mITT population while 29 subjects were excluded from PP population out of 1176 subjects randomized in the study</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="391"/>
                <count group_id="O2" value="393"/>
                <count group_id="O3" value="391"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2332" spread="0.1160"/>
                    <measurement group_id="O2" value="2.0287" spread="0.1157"/>
                    <measurement group_id="O3" value="-0.6387" spread="0.1172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The over all time frame for any the Adverse Events is maximum 9days starting from date of appearance to date of disappearance.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Diclofenac Sodium Topical Gel, 1%</title>
          <description>Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks&#xD;
Diclofenac Sodium Topical Gel, 1%: Opaque, white gel</description>
        </group>
        <group group_id="E2">
          <title>Voltaren Topical Gel, 1%</title>
          <description>Voltaren Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks&#xD;
Voltaren Topical Gel, 1%: Opaque, white gel</description>
        </group>
        <group group_id="E3">
          <title>Vehicle Diclofenac Sodium Topical Gel</title>
          <description>Vehicle Diclofenac Sodium Topical Gel. 4 gm, 4 times a day for 4 weeks&#xD;
Vehicle Diclofenac Sodium Topical Gel: Opaque, white gel</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="391"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema,</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus and Rash Pruritic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Candis Edwards</name_or_title>
      <organization>Amneal Pharmaceuticals</organization>
      <phone>631-974-7949</phone>
      <email>cedwards@amneal.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

